Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) Weakness Creates Buying Opportunity, Says Analyst
May 2, 2014 1:28 PM EDTH.C. Wainwright reiterated a Buy rating on Seattle Genetics (NASDAQ: SGEN) with a price target of $65. Analyst Andrew S. Fein thinks recent macro weakness has opened a buying opportunity.
"Yesterday, SGEN reported 1Q14 financial results and gave an update on its development and clinical activities, which demonstrates that the underlying value of its... More
